Human primary CD34+ Hematopoietic stem and Progenitor cells
Closed Solicitation Posted
- Solicitation number
- FDA-SOL-1233197
- Agency
- FDA Office of Acquisition and Grant Services Food and Drug Administration, Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325413 In-Vitro Diagnostic Substance Manufacturing
- Place of performance
- Silver Spring MD 20993 USA
Notice details come from SAM.gov. Updated .
Notice text
The U.S. Food and Drug Administration (FDA), Center for Biologics Evaluation and Research (CBER) / Division of Cell and Gene Therapy (DCGT), Office of Cellular, Tissue and Gene Therapy requires Human primary CD34+ hematopoietic stem and progenitor cells to have assessed identity and characterization of gene and cell therapy products to perform critical path research for its mission to develop and promote technology to regulate cellular and genetic therapeutics.
Attachments
| File | Type | Posted |
|---|---|---|
| FDA_SOL_1233197.pdf |
On GovTribe
Work this opportunity on GovTribe
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity